Matteo S Carlino

12PUBLICATIONS
120CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 13, 2026
An anti-PMEL antibody-drug conjugate with a G<sub>q/1</sub><sub>1</sub> inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial.

|Jun 01, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

|Apr 24, 2026
Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

|Mar 12, 2026
Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

Andrea Boutros, Matteo S Carlino, Raja Chaganti

|Feb 03, 2026
Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients.

Sophie Walter, Francesca Watts, Raquel Ruiz Araujo

|Dec 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.

Jason J Luke, Karen Gelmon, Lillian L Siu

Pageof 2

Frequent Collaborators

4 joint publications

Adnan Nagrial

4 joint publications

Georgina V Long

3 joint publications

Alexander M Menzies

3 joint publications

Raquel Ruiz Araujo